742 related articles for article (PubMed ID: 15193029)
21. B cells and antibodies in multiple sclerosis pathogenesis and therapy.
Krumbholz M; Derfuss T; Hohlfeld R; Meinl E
Nat Rev Neurol; 2012 Nov; 8(11):613-23. PubMed ID: 23045237
[TBL] [Abstract][Full Text] [Related]
22. Defining the clinical course of multiple sclerosis: the 2013 revisions.
Lublin FD; Reingold SC; Cohen JA; Cutter GR; Sørensen PS; Thompson AJ; Wolinsky JS; Balcer LJ; Banwell B; Barkhof F; Bebo B; Calabresi PA; Clanet M; Comi G; Fox RJ; Freedman MS; Goodman AD; Inglese M; Kappos L; Kieseier BC; Lincoln JA; Lubetzki C; Miller AE; Montalban X; O'Connor PW; Petkau J; Pozzilli C; Rudick RA; Sormani MP; Stüve O; Waubant E; Polman CH
Neurology; 2014 Jul; 83(3):278-86. PubMed ID: 24871874
[TBL] [Abstract][Full Text] [Related]
23. Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis.
Palanichamy A; Apeltsin L; Kuo TC; Sirota M; Wang S; Pitts SJ; Sundar PD; Telman D; Zhao LZ; Derstine M; Abounasr A; Hauser SL; von Büdingen HC
Sci Transl Med; 2014 Aug; 6(248):248ra106. PubMed ID: 25100740
[TBL] [Abstract][Full Text] [Related]
24. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.
Krumbholz M; Theil D; Cepok S; Hemmer B; Kivisäkk P; Ransohoff RM; Hofbauer M; Farina C; Derfuss T; Hartle C; Newcombe J; Hohlfeld R; Meinl E
Brain; 2006 Jan; 129(Pt 1):200-11. PubMed ID: 16280350
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory cortical demyelination in early multiple sclerosis.
Lucchinetti CF; Popescu BF; Bunyan RF; Moll NM; Roemer SF; Lassmann H; Brück W; Parisi JE; Scheithauer BW; Giannini C; Weigand SD; Mandrekar J; Ransohoff RM
N Engl J Med; 2011 Dec; 365(23):2188-97. PubMed ID: 22150037
[TBL] [Abstract][Full Text] [Related]
26. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Choi SR; Howell OW; Carassiti D; Magliozzi R; Gveric D; Muraro PA; Nicholas R; Roncaroli F; Reynolds R
Brain; 2012 Oct; 135(Pt 10):2925-37. PubMed ID: 22907116
[TBL] [Abstract][Full Text] [Related]
27. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Hawker K; O'Connor P; Freedman MS; Calabresi PA; Antel J; Simon J; Hauser S; Waubant E; Vollmer T; Panitch H; Zhang J; Chin P; Smith CH;
Ann Neurol; 2009 Oct; 66(4):460-71. PubMed ID: 19847908
[TBL] [Abstract][Full Text] [Related]
28. Multiple sclerosis.
Compston A; Coles A
Lancet; 2008 Oct; 372(9648):1502-17. PubMed ID: 18970977
[TBL] [Abstract][Full Text] [Related]
29. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis.
Lovato L; Willis SN; Rodig SJ; Caron T; Almendinger SE; Howell OW; Reynolds R; O'Connor KC; Hafler DA
Brain; 2011 Feb; 134(Pt 2):534-41. PubMed ID: 21216828
[TBL] [Abstract][Full Text] [Related]
30. Progressive multiple sclerosis: pathology and pathogenesis.
Lassmann H; van Horssen J; Mahad D
Nat Rev Neurol; 2012 Nov; 8(11):647-56. PubMed ID: 23007702
[TBL] [Abstract][Full Text] [Related]
31. Identification of autoantibodies associated with myelin damage in multiple sclerosis.
Genain CP; Cannella B; Hauser SL; Raine CS
Nat Med; 1999 Feb; 5(2):170-5. PubMed ID: 9930864
[TBL] [Abstract][Full Text] [Related]
32. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.
Cepok S; Rosche B; Grummel V; Vogel F; Zhou D; Sayn J; Sommer N; Hartung HP; Hemmer B
Brain; 2005 Jul; 128(Pt 7):1667-76. PubMed ID: 15800022
[TBL] [Abstract][Full Text] [Related]
33. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain.
Serafini B; Rosicarelli B; Franciotta D; Magliozzi R; Reynolds R; Cinque P; Andreoni L; Trivedi P; Salvetti M; Faggioni A; Aloisi F
J Exp Med; 2007 Nov; 204(12):2899-912. PubMed ID: 17984305
[TBL] [Abstract][Full Text] [Related]
34. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells.
Crawford A; Macleod M; Schumacher T; Corlett L; Gray D
J Immunol; 2006 Mar; 176(6):3498-506. PubMed ID: 16517718
[TBL] [Abstract][Full Text] [Related]
35. The Charcot Lecture | beating MS: a story of B cells, with twists and turns.
Hauser SL
Mult Scler; 2015 Jan; 21(1):8-21. PubMed ID: 25480864
[TBL] [Abstract][Full Text] [Related]
36. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.
Duddy M; Niino M; Adatia F; Hebert S; Freedman M; Atkins H; Kim HJ; Bar-Or A
J Immunol; 2007 May; 178(10):6092-9. PubMed ID: 17475834
[TBL] [Abstract][Full Text] [Related]
37. B cells and multiple sclerosis.
Franciotta D; Salvetti M; Lolli F; Serafini B; Aloisi F
Lancet Neurol; 2008 Sep; 7(9):852-8. PubMed ID: 18703007
[TBL] [Abstract][Full Text] [Related]
38. B-cell differentiation in the CNS of patients with multiple sclerosis.
Corcione A; Aloisi F; Serafini B; Capello E; Mancardi GL; Pistoia V; Uccelli A
Autoimmun Rev; 2005 Nov; 4(8):549-54. PubMed ID: 16214094
[TBL] [Abstract][Full Text] [Related]
39. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X; Hauser SL; Kappos L; Arnold DL; Bar-Or A; Comi G; de Seze J; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Rammohan KW; Selmaj K; Traboulsee A; Sauter A; Masterman D; Fontoura P; Belachew S; Garren H; Mairon N; Chin P; Wolinsky JS;
N Engl J Med; 2017 Jan; 376(3):209-220. PubMed ID: 28002688
[TBL] [Abstract][Full Text] [Related]
40. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
